Explore market opportunities by mastering the EU system for variations. Gain insights on optimizing regulatory procedures, crafting global dossiers, and achieving faster approvals. Enhance your ...
TOKYO & MUNICH, December 18, 2025--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) for the treatment of adult patients with HER2 ...